SS-31: The Mitochondria-Targeting Peptide for Energy and Longevity

Every cell in your body runs on mitochondria. These organelles — often described as the cell's powerhouses — produce the ATP that fuels every contraction, thought, and metabolic process your body undertakes. As we age, mitochondrial function declines, and that decline is increasingly viewed not just as a consequence of aging, but as one of its primary drivers.

SS-31 (also called elamipretide, or by its research designation Szeto-Schiller peptide 31) represents one of the most targeted interventions in mitochondrial medicine. Unlike broad-spectrum antioxidants that scavenge free radicals indiscriminately, SS-31 homes in on the specific molecular machinery that keeps mitochondria running efficiently.

What Is SS-31?

SS-31 is a tetrapeptide — a molecule made of four amino acids — developed by researchers Hazel Szeto and Peter Schiller. Its unique structure gives it a high positive charge that allows it to selectively accumulate within the inner mitochondrial membrane, reaching concentrations roughly 1,000-fold higher inside mitochondria than in the surrounding cytoplasm.

This targeted delivery is what makes SS-31 pharmacologically distinct. Most antioxidants, when taken orally or injected, distribute throughout the body without meaningful mitochondrial specificity. SS-31 gets directly to the site of dysfunction.

The Cardiolipin Connection

The inner mitochondrial membrane contains a phospholipid called cardiolipin, which is essential for the proper function of the electron transport chain (ETC) — the series of protein complexes that generate ATP. Cardiolipin also plays a role in maintaining the structural integrity of the membrane and regulating key processes like mitophagy (the recycling of damaged mitochondria).

During aging and in pathological states, cardiolipin becomes oxidized and dysfunctional. This impairs electron transport chain efficiency, increases electron leakage (which produces damaging reactive oxygen species), and reduces the mitochondria's ability to produce ATP.

SS-31 binds to cardiolipin and protects it from oxidation. In doing so, it helps restore electron transport chain function, reduces mitochondrial ROS production, and improves the overall bioenergetic efficiency of the cell.

What the Research Shows

SS-31 has been studied across a wide range of aging-related conditions, with results that have attracted significant scientific interest:

Heart Failure: SS-31 (under the clinical name elamipretide) entered phase II and phase III clinical trials for heart failure with reduced ejection fraction. Early results showed improved cardiac function and exercise tolerance. In animal models, it consistently reverses age-related cardiac dysfunction within weeks of treatment.

Skeletal Muscle and Exercise: Studies in aged mice showed that SS-31 treatment restored muscle fiber mitochondrial function and improved physical performance to levels comparable to young animals. The peptide appears to rescue the age-related decline in fast-twitch muscle fiber function without exercise training.

Kidney Protection: Multiple studies have demonstrated SS-31's ability to protect the kidneys from ischemia-reperfusion injury — the damage that occurs when blood supply is restored after being cut off, common in surgical settings.

Neurodegeneration: Preclinical research suggests SS-31 may protect neurons from mitochondrial dysfunction associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

Lifespan Extension: In model organisms, SS-31 has demonstrated the ability to extend lifespan and healthspan markers, consistent with its mitochondrial protective mechanism.

How It's Used

SS-31 is a research peptide not currently approved by the FDA for general clinical use (outside of specific trial contexts). It is administered subcutaneously, typically at doses ranging from 0.1–10 mg/kg in research settings, though human protocols in biohacking communities tend to be much lower.

Because it lacks oral bioavailability, SS-31 must be injected. The peptide is relatively stable and typically well-tolerated in research subjects.

Side Effects and Safety Profile

In clinical trials, SS-31/elamipretide has shown a generally favorable safety profile. The most commonly reported adverse effects are injection site reactions — redness, irritation, or mild discomfort at the injection site. No serious systemic adverse events have been consistently attributed to the peptide across trials.

As with any research compound used outside a clinical trial, long-term safety data in healthy humans is limited.

Why It Matters for Longevity

The mitochondrial theory of aging posits that accumulated mitochondrial damage — particularly oxidative stress and dysfunction of the electron transport chain — is a primary mechanism underlying the aging process. If that's correct, then compounds that specifically protect and restore mitochondrial function could have outsized effects on healthspan and lifespan.

SS-31 is one of the few compounds with a clear, mechanistic explanation for why it works, robust preclinical data across multiple aging models, and an active clinical trial history. That combination puts it in a different category from most longevity supplements.

Key Takeaway

SS-31 targets the root of mitochondrial dysfunction with remarkable specificity — protecting cardiolipin, restoring electron transport chain efficiency, and reducing oxidative damage at the source. If the mitochondrial theory of aging holds, SS-31 may be among the most rationally designed anti-aging interventions currently under investigation.